The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PANZYGA (Octapharma Australia Pty Ltd)
Product name
PANZYGA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
212 working days (255)
Active ingredients
human immunoglobulin G
Registration type
NCE/NBE
Indication
PANZYGA (solution for intravenous infusion) is indicated for:
Replacement therapy in:
- Primary immunodeficiency diseases
- Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent bacterial infections
- Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment
Immunomodulation in:
- Idiopathic thrombocytopenic purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
- Guillain Barré syndrome
- Kawasaki disease